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AS SUBMITTED TO:
Ear, nose, & throat journal.
AND LATER PUBLISHSED AS:

MALIGNANT MELANOMA METASTASIZING TO THE THYROID
GLAND

2009 Jan;88(1):E7.
BRIAN KUNG, MD; SABA AFTAB, BS; MOIRA WOOD, MD; DAVID ROSEN, MD

INTRODUCTION
Metastatic disease in the thyroid gland accounts for less than 1% of cases of thyroid
cancer1,2 . The most common sources of metastases are renal cell carcinoma, breast carcinoma,
and lung carcinoma3-6. Clinically apparent metastatic melanoma to the thyroid gland is rare,
accounting for less than 5% of metastatic tumors to the thyroid6.
We present a case of a patient with malignant melanoma metastatic to the thyroid gland
as the first manifestation of distant metastatic disease.
CASE

Figure 1: a) S-100 stain of melanoma cells from FNA specimen, b) Melan-A stain from FNA specimen

A 68-year-old male with a 30 pack year tobacco history presented with a left posterior
triangle neck mass measuring 1.5 cm. Physical exam and radiographic studies performed at the
time failed to reveal a primary tumor—just the posterior triangle mass. An FNA of the mass at
the time revealed a poorly differentiated squamous cell carcinoma. The patient was taken to the
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operating room for direct laryngoscopy with biopsy, left tonsillectomy, esophagoscopy and
bronchoscopy with bronchoalveolar lavage, as well as repeat FNA of the neck mass. Again,
there was no evidence of a primary lesion. However, FNA at this time was suggestive of
melanoma, and this diagnosis was confirmed via immunophenotyping, which showed the cells
staining positive for Melan-A and S-100 (Figure 1). Biopsies of the left tonsil, nasopharynx and
left tongue base were all negative. The patient then underwent a left modified radical neck
dissection. The posterior triangle neck mass was discovered to be a lymph node which tested
positive for malignant melanoma. All other nodes were negative. No primary site for the
malignant melanoma was found, and the patient was scheduled for postoperative radiation
therapy and chemotherapy. However, the patient was reluctant to receive these treatments and
subsequently was not further treated.
Eighteen months later, the patient presented with a midline neck mass representing a
diffusely enlarged thyroid gland. The gland measured 10cm in diameter (Figure 2). An FNA of
the mass was performed which revealed malignant cells consistent with a melanoma and
confirmed by positive Melan-A and S-100 stains.
Figure 2: Patient’s neck mass presenting as enlarged thyroid
gland.

The patient underwent an MRI of the neck, revealing
a diffusely enlarged cystic thyroid gland without
associated cervical adenopathy (Figure 3).
Approximately two weeks later, the patient began
having seizures, and an MRI of the brain revealed a
1.7cm mass in the region of the anterior superior
vermis, with associated mass effect and mild
hydrocephalus (Figure 4). This was suspicious for
metastatic melanoma. At this time, a CT scan of the
chest, abdomen, and pelvis was obtained, showing a soft tissue lesion in the suprapubic region
consistent with metastatic melanoma.

Figure 3: a) Axial T1W MRI showing enlarged thyroid gland, b) Coronal T2W MRI showing similar findings.
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Figure 4: a) Sagittal T1W MRI showing enhancing lesion of anterior vermis with associated hydrocephalus, b) axial
T1W MRI showing similar findings.

The patient soon developed ventilator dependent respiratory failure, and he was taken to the
operating room for a subtotal thyroidectomy for establishment of a tracheostomy (Figure 5).

Figure 5: a) Intraoperative view of enlarged thyroid gland; b) division of thyroid gland to facilitate removal prior to
tracheostomy; c) gross subtotal thyroid specimen removed. Note the extensively pigmented thyroid parenchyma.

Histologic specimens showed the thyroid largely being replaced by metastatic melanoma with
extensive necrosis (Figure 6). The patient subsequently required placement of a
ventriculoperitoneal shunt to treat the hydrocephalus secondary to the metastatic lesion in his
posterior fossa.

Figure 6: a) H&E stain, 2x view showing extensive replacement of thyroid parenchyma by nests of melanoma and
considerable necrosis; b) 20x view showing melanoma on the left and thyroid on the right—two thyroid follicles are
seen; c) the 40x view best shows the pigment and hemosiderin among the melanoma tubes.

DISCUSSION
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The case presented above is similar to the few other case reports detailing metastatic
melanoma to the thyroid gland. Our patient’s presenting symptom was a lump in the neck, and
studies have shown this to be the most common complaint among patients with metastatic
disease to the thyroid gland7,8. Other authors have found that the pathology of the thyroid shows
total replacement of the gland by metastatic melanoma, yet with preservation of thyroid
function9-11. Our patient, too, had no clinical evidence of hypothyroidism. His laboratory thyroid
abnormalities (slightly decreased TSH, normal free T4) more likely represent the slight variation
in thyroid function tests seen in euthyroid sick syndrome. Shimaoka et al describe a likely
explanation for this phenomenon—it takes weeks to months for total ablation of thyroid function
to manifest as hypothyroidism, and most patients do not survive long enough with metastatic
tumor for hypothyroidism to become apparent12. Additionally, although it has been suggested
that pre-existing abnormalities of the thyroid, such as nodules or adenomas, predisposes it to
metastatic lesions13,14, our patient, like that of Mitra’s9, did not have any such abnormalities upon
pathological examination of the gland or upon clinical history.
Various autopsy studies have revealed the incidence of malignant melanoma
metastasizing to the thyroid gland to be high. Although Nakhjavani et al6 found melanoma to
account for less than 5% of clinically apparent metastatic thyroid tumors, autopsy studies have
shown the number to be much higher – as high as 35% of all metastatic lesions to the thyroid13.
The disparity can be explained by the fact that in autopsy studies, metastatic lesions are
discovered only upon microscopic examination of small, careful cuts of the gland. Small foci of
metastases may not present clinically as a thyroid nodule or goiter. In autopsy studies focused
only on patients with melanoma, Patel et al found the incidence of thyroid metastases to be 26%
in the 261 autopsies performed15. In a similar study of 41 patients with melanoma, Shimaoka et
al found thyroid metastases in 39%12. It is not surprising that melanoma has such a high
propensity for the thyroid gland given that the thyroid is a highly vascular organ and melanoma
spreads via the hematogenous route. In fact, melanoma has the ability to metastasize to almost
every organ given its aggressive nature. The most common sites of metastases for melanoma are
lymph node, lungs, liver and brain15. Thus, although patients with melanoma may commonly
have thyroid metastases without clinical consequence, it is rare that a mass in the thyroid would
be their only clinically apparent sign of metastatic melanoma. Although our patient was
discovered to have additional inguinal lymph node and brain metastases during his hospital
course, it was his thyroid nodule that was the first indication of metastatic disease.
Metastases of any malignancies to the thyroid are much more common than one would
expect. The incidence of metastatic growths in the thyroid gland when patients are known to
have metastatic tumors is fairly high. In a large autopsy study in Malmo of 7332 patients with
known malignancy, 2.8% were found to have thyroid metastases18. Other studies have found the
incidence as high as 9.5%12. Combining various autopsy studies, a more representative figure is
5-6%. These surprising numbers have prompted some to state that metastatic thyroid neoplasms
may be 10 times as numerous as primary thyroid cancers12. Watts reports that FNA of six
patients presenting with a thyroid nodule who had a past history of malignancy, four had
cytologic evidence of malignancy, representing 66%16. This led him to conclude, along with
Shimaoka et al, that in a patient with a history of cancer, a malignant thyroid nodule is much
more likely than a primary12,16.
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Our case allows for discussion of the diagnosis and management of thyroid metastases.
FNA has been reported to be the initial procedure of choice in diagnosis of metastatic lesions to
the thyroid, and it carries low morbidity16,17. In our patient, although the initial FNA of his left
neck mass misrepresented melanoma as poorly differentiated squamous cell carcinoma, his
subsequent two FNAs of the left neck mass and the thyroid mass confirmed melanoma with the
help of immunohistochemical stains. The FNA in this patient was useful in guiding management
of the patient. Clearly a metastatic lesion to the thyroid must be managed very differently than a
lymphoma or a primary thyroid tumor. In general, secondary neoplasm to the thyroid is usually
an indicator of poor prognosis. Metastatic cancer to the thyroid predominates in the sixth,
seventh and eighth decade of life, and these patients in general have a worse prognosis secondary
to advanced age5,8. More importantly, thyroid metastases are usually part of a widely
disseminating malignancy. In most case series of metastases to the thyroid gland, other
metastatic deposits are identified at or soon after the discovery of the lesion. With the exception
of metastases from renal cell carcinoma, Rosen et al showed patient survival less than 2 years
after discovery of thyroid metastases17. McCabe et al had an average survival of 12 months in
their 17 patients with metastases to the thyroid8. In discussing melanoma specifically, patients
with metastatic melanoma have a median survival of 24 months, irrespective of site of
metastasis15. Less than 1% of melanoma patients have single organ metastasis, and when
combined with other poor prognostic indicators, surgical management of metastatic melanoma is
most often limited to palliative measures15. Thyroidectomy is an accepted procedure for
palliation from dyspnea or dysphagia, or as in our patient, placement of tracheostomy tube. In
the rare case that the thyroid is the only site of metastatic deposits, thyroidectomy can be
curative7.
Any patient with a history of malignancy and a thyroid nodule presents a diagnostic
dilemma. Is this a benign nodule, a new primary, or a metastasis? The FNA can be very helpful
in distinguishing these entities. If it represents metastatic disease, is this a “new” metastases
suggesting a neoplastic recurrence, or is this merely the growth of microscopic deposits from a
much earlier neoplasm? Others have authored similar dilemmas - Ivy describes melanoma in the
thyroid gland years before and years after the primary is ever discovered5. Nakhjavani et al
report months between detection of primary malignancy and metastases to the thyroid6. In our
patient, the thyroid metastasis presented 18 months after initial diagnosis of metastatic
melanoma. Did his thyroid metastases represent a new primary, or was it the remnant deposits
from an inadequately treated initial melanoma? In our case, it is especially difficult as a primary
neither for the initial lesion, nor for the thyroid and brain metastases was ever found. However,
given the high incidence of thyroid metastases in malignancy, and given the long time period
between initial neoplasm and discovery of thyroid metastases, we must agree with Nakhjavani et
al that any patient with a previous history of malignancy with a thyroid mass should be
considered as having metastases until proven otherwise6.
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